ONTO INNOVATION INC. (ONTO): what the price assumes

In the published model solve dated 2026-Q2, anchored at $275.75, ONTO INNOVATION INC. (ONTO) is priced for today's economics sustained for ~31.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/ONTO

Headline

FieldValue
TickerONTO
CompanyONTO INNOVATION INC.
Current price$275.75/sh
CompositionSystems and software 84% / Parts 8% / Services 7%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Must persist for31.2y
Multiple paid130x operating income

Solve inputs: computed at a 13.9% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~16.9 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.66σ
sustained it ~10 years at this level14%
implied end-window share1%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset14.75x4expensive
Earnings8.71x4expensive
Relative5.35x3expensive
Growth3.55x3expensive

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$42.316.52xyesFCF base $0.2B, growth 0% (input: historical growth), terminal g 0.5%, WACC 9.2%, 5yr projection
DCF Exit MultipleGrowth$152.401.81xyesExit EV/EBITDA: 117.1x / 119.1x / 121.1x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$74.523.70xyesP/E 39.6x (blended: static sector reference 18x + trailing (TTM) 130x), scenarios: 33.4x / 39.6x / 45.8x (bear / base = reference held flat / bull), EV/EBITDA 26.4x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$23.0111.98xyesBV/sh $42.64, ROE (TTM) 5.0%, ke 9.3%
Two-Stage Excess ReturnAsset$15.7517.51xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$77.713.55xyesRev $1.0B, growth 0% (input: historical growth; tapered), Terminal P/S: 6.8x / 8.0x / 9.2x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$17.4015.85xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.10B × (1−11%) / WACC 9.2% → EPV (no growth)
Residual IncomeAsset$14.9118.49xyesBV $42.64 + 5yr PV of (ROE (TTM) 5.0% − Kₑ 9.3%) × BV; BV grows 3.2%/yr
Graham NumberAsset$45.426.07xyes√(22.5 × EPS $2.15 × BVPS $42.64) — Graham's conservative floor
EV/EBITDA RelativeRelative$31.438.77xyesEBITDA $0.11B × sector EV/EBITDA 12.0x
FCF YieldEarnings$55.684.95xyesFCF $238.8M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$49.665.55xyesSBC-adj FCF $0.21B (FCF $0.24B − SBC $0.03B) capitalized at Kₑ
Ben Graham FormulaEarnings$1.80153.19xyesEPS $2.15 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$7.1138.78xyesBV $42.64 × (ROIC 1.5% / WACC 9.2%) (excluded from median)
P/Sales SectorRelative$51.535.35xyesRevenue $1.03B × sector P/S 2.5x
PEG Fair ValueRelativeno
Earnings YieldEarnings$23.2411.87xyesEPS $2.15 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Process characterization metrology, inspection, lithography & softwareoperatingenterprise1.0B reported-currencywithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net cash$654.2m
Net debt / NOPAT (after-tax)-7.14x (net cash)
Net debt / operating income (pre-tax)-6.33x (net cash)
Share count CAGR (dilution)0.0%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

The trajectory is what carries Onto. Q1 2026 brought record revenue of $292 million, nearly 10% sequential growth and above guidance, with EPS of $1.42 and management guiding full-year revenue growth above 30%. Margins are expanding alongside revenue.

The price discounts that trajectory far out. At $333.52 no valuation family reaches the price; the supported range is near $39 with a base in the high $30s. Inverting the price implies sustaining high growth for about 30 years, which is why the reliability flag is low and the rarity check is elevated.

The balance sheet is clean: about $654 million in cash, no debt. There is no financial risk. The bet is entirely on whether the AI-packaging and advanced-node metrology demand that is driving the current acceleration proves as durable as the price assumes.

Bull Case

Lead with the earnings trajectory, because the direction of the numbers is the heart of the bull case. Onto's revenue, margins and growth rate are all accelerating at once. Q1 2026 delivered record revenue of $292 million, nearly 10% sequential growth and above the $275 to $285 million guidance, with EPS of $1.42 ahead of expectations. Management guided Q2 to $320 to $330 million, the midpoint up about 28% year over year, with gross margin of 56% to 56.5%, and framed full-year 2026 revenue growth above 30%. A company posting record quarters, raising the trajectory, and expanding margin into the strength is showing operating momentum, not a one-quarter pop.

The driver behind the momentum is the right one: advanced semiconductor manufacturing. Onto's metrology and inspection systems provide process control across the industry, and the 10-K describes integrating these technologies "to meet our customers' changing process requirements" with tools that provide "process control for the majority of" critical steps (FY2025 10-K, accession 0001193125-26-066937). The specific wins are at the leading edge: the Dragonfly G5 system was qualified at a 2.5D logic customer and a high-bandwidth-memory customer, and the new Atlas G6 was selected by a second logic customer for gate-all-around metrology, helping drive 13% advanced-node growth in the quarter. These are the exact process steps that AI chips and advanced packaging require, and they are growing fastest.

The runway is sized to the AI buildout. Management expects Dragonfly platform demand to grow more than 50% in 2026 and AI device-packaging demand to grow roughly 30% annually over the next two years. Onto sits at a control point in that supply chain, and it does so with a pristine balance sheet: about $654 million in cash and no debt. It can fund R&D and capacity expansion internally while the demand wave builds. A profitable, debt-free metrology leader with accelerating revenue, expanding margins, leading-edge tool wins and a multi-year AI-packaging tailwind is the kind of business whose forward earnings can grow into a rich multiple, which is the bull's answer to a price the static methods call full.

Bear Case

The bear case is about which assumptions are baked into the price and which is most fragile. At $333.52 (June 27, 2026) no valuation family reaches the price, and the implied-expectations read requires sustaining high growth for about 30 years. The price is underwriting two specific narratives: that AI-packaging and advanced-node metrology demand grows at the rates management projects, and that Onto keeps its share of those steps for decades. The most fragile of these is the durability of the AI-driven demand. The current acceleration is real, but it is concentrated in a buildout cycle that, like every semiconductor cycle before it, will eventually digest. A pause in AI capital spending would hit the fastest-growing, highest-expectation part of Onto's business first.

The competitive narrative is the second fragility. Onto names its principal competitors directly: in automated systems for the semiconductor industry, they are "KLA Corporation and Nova Ltd." (FY2025 10-K, accession 0001193125-26-066937). KLA in particular is far larger and dominates process control. Onto's leading-edge tool wins are impressive, but holding and extending share against a much bigger incumbent across a 30-year horizon is a strong assumption to embed in the price. If KLA or Nova contests the gate-all-around or advanced-packaging metrology that is driving Onto's growth, the share gains that justify the multiple could stall or reverse.

The structural reality compounds both. The 10-K is explicit that Onto operates "in the highly concentrated, capital-intensive semiconductor device manufacturing industry" and that "historically, a substantial portion of our revenue in each quarter and year" comes from a small number of customers (same 10-K). Customer concentration means a single large customer's spending decision can swing a quarter, and capital-intensive customers cut tool orders sharply in downturns. Trailing operating margin is around 10%, far below the price's implied steady-state, and the rarity check is elevated with the fade assumption tripped. The bear case is not that Onto is a bad business; it is that the price has discounted three decades of high growth, sustained share against larger rivals, and no cyclical interruption, leaving no margin for the AI narrative to cool or the competitive position to slip.

Valuation

Onto's valuation sits above every method. The blended central estimate is near $42 against a price of $333.52, and no family reaches the price: the asset family values the stock at roughly a tenth of the price, the earnings-power family similarly, the peer-multiple family at about a sixth, and even the forward-growth family well below. The most generous individual reads, a DCF exit multiple near $181 and a discounted future market cap near $78, still fall far short of the price. The supported range runs from about $33 to $48, with low reliability, which tells you the methods agree the price is rich but cannot pin a precise number on a business growing this fast.

The inversion makes the assumption explicit. With trailing operating margin around 10%, backing out the price requires sustaining growth near the high-end ceiling for about 30 years. That is among the longest durations a cyclical capital-equipment business can carry, and the rarity assessment is elevated with the fade check tripped, signaling that such persistence is well outside the base rate. The price is not valuing Onto on its current earnings; it is valuing it on three decades of the AI-packaging and advanced-node growth wave continuing largely uninterrupted and Onto retaining its position throughout.

The balance sheet is a clean positive that does not change the central estimate. About $654 million in cash and no debt mean Onto can invest through any cycle without financial strain, and the share count is flat, so there is no dilution dragging on per-share value. That financial strength is part of why a premium is defensible for a quality metrology leader. What it cannot do is shorten the 30-year duration the price requires or insulate the business from the semiconductor cycle and from competition with KLA and Nova. The methods are unanimous that the price embeds a best-case, long-duration outcome; the investment question is whether conviction in the AI-metrology runway justifies paying a price that every standard frame says is well above the business as it stands today.

Catalysts

Onto Innovation reported record Q1 2026 revenue of $292 million, nearly 10% sequential growth and above the $275 to $285 million guidance, with EPS of $1.42 beating estimates (Q1 2026 earnings release). The quarter was driven by leading-edge wins: the Dragonfly G5 qualified at a 2.5D logic and a high-bandwidth-memory customer, and the Atlas G6 selected by a second logic customer for gate-all-around metrology, helping drive 13% advanced-node growth (Onto IR).

The catalysts ahead are the demand-growth and margin trajectory. Management guided Q2 2026 to $320 to $330 million of revenue, 56% to 56.5% gross margin, and non-GAAP EPS of $1.65 to $1.73, with full-year revenue growth above 30%; it expects Dragonfly demand to grow more than 50% in 2026 and AI device-packaging demand to grow roughly 30% annually over two years (Investing.com). Watch three things over the coming quarters: whether revenue keeps tracking toward the 30%-plus full-year guide, whether gross margin expands as the mix shifts to advanced nodes, and whether new tool qualifications and customer wins keep widening the leading-edge position against KLA and Nova. Sustained advanced-node growth with margin expansion would support the trajectory the price assumes; an AI-spending pause, a competitive loss, or a customer-concentration air pocket would pull the stock back toward the methods, which all sit far below the current price.

Peer Cohorts (Per Segment, With Filing Citations)

Process characterization metrology, inspection, lithography & software (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive ONTO report on boothcheck